Breaking News
Wednesday , August 23 2017
Home / Business / Lupin gets six observations from USFDA for Indore plant: Report

Lupin gets six observations from USFDA for Indore plant: Report

Lupin has reportedly received 6 USFDA Form 483 observations for its Indore plant. The facility was inspected by the US drug regulator between May 8 and May 19, 2017. Earlier, USFDA has issued eight observations for the company’s Aurangabad unit, which was inspected between April 17 and 26, 2017.

Lupin is a pharmaceutical company and is engaged in formulation of drugs and active pharmaceutical ingredients (APIs), generics, biotechnology, novel drug discovery and development, drug delivery systems and specialty pharmaceuticals.

Loading...

About editor

Close